Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.


Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Liu SY, Dong ZY, Wu SP, Xie Z, Yan LX, Li YF, Yan HH, Su J, Yang JJ, Zhou Q, Zhong WZ, Tu HY, Yang XN, Zhang XC, Wu YL.

Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14.


LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR.

J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.


PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).

Jiang L, Su X, Zhang T, Yin X, Zhang M, Fu H, Han H, Sun Y, Dong L, Qian J, Xu Y, Fu X, Gavine PR, Zhou Y, Tian K, Huang J, Shen D, Jiang H, Yao Y, Han B, Gu Y.

Oncotarget. 2017 Apr 18;8(16):26845-26857. doi: 10.18632/oncotarget.15839.


Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.

Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, He X, Liu L, Zhou T, Huang J, Chen Y, Qin T, Zhang Y, Ma Y, Yang Y, Zhao Y, Huang Y, Zhang L.

Oncoimmunology. 2015 Dec 21;5(3):e1094598. eCollection 2016 Mar.


Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.

Zhao M, Zhan C, Li M, Yang X, Yang X, Zhang Y, Lin M, Xia Y, Feng M, Wang Q.

J Thorac Dis. 2018 Jan;10(1):398-407. doi: 10.21037/jtd.2017.12.68.


EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.

Koh J, Jang JY, Keam B, Kim S, Kim MY, Go H, Kim TM, Kim DW, Kim CW, Jeon YK, Chung DH.

Oncoimmunology. 2015 Oct 29;5(3):e1108514. eCollection 2016 Mar.


Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC.

Eur J Cancer. 2016 Apr;57:91-103. doi: 10.1016/j.ejca.2015.12.033. Epub 2016 Feb 21.


Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.

Clin Cancer Res. 2015 Sep 1;21(17):4014-21. doi: 10.1158/1078-0432.CCR-15-0016. Epub 2015 May 27.


Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS.

Cancer Res Treat. 2019 Jul;51(3):1231-1240. doi: 10.4143/crt.2018.486. Epub 2018 Dec 31.


PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.

Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, Yin CC, You MJ, Khoury JD, Iyer SP, Miranda RN, Xu J.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0336-3. [Epub ahead of print]


Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X.

Clin Lung Cancer. 2015 Sep;16(5):e25-35. doi: 10.1016/j.cllc.2015.02.002. Epub 2015 Feb 19.


Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo MEB, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.

Cancer Immunol Res. 2015 Dec;3(12):1333-1343. doi: 10.1158/2326-6066.CIR-15-0089. Epub 2015 Sep 29.


Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.


Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.

Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P, Lorenzo M, Menéndez S, Salido M, Albanell J, Pijuan L, Arriola E.

Clin Lung Cancer. 2017 Nov;18(6):682-691.e5. doi: 10.1016/j.cllc.2017.04.014. Epub 2017 May 4.


PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.

Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK.

Lung Cancer. 2016 Mar;93:9-16. doi: 10.1016/j.lungcan.2015.12.006. Epub 2015 Dec 30.


Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.

Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, Auliac JB, Gervais R, Chouaid C.

Target Oncol. 2017 Oct;12(5):563-569. doi: 10.1007/s11523-017-0510-9. Review.


Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ.

Gut. 2017 May;66(5):794-801. doi: 10.1136/gutjnl-2015-310839. Epub 2016 Jan 22.


The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.

Yang H, Chen H, Luo S, Li L, Zhou S, Shen R, Lin H, Xie X.

Oncotarget. 2017 Apr 4;8(14):23517-23528. doi: 10.18632/oncotarget.15627.

Supplemental Content

Support Center